R. Chase

发表

Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors.

M. Rudd, P. Coleman, J. Vacca, 2014, ACS medicinal chemistry letters.

Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.

X. Tong, M. Maccoss, R. Reynolds, 2012, Bioorganic & medicinal chemistry letters.

5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.

X. Tong, M. Maccoss, R. Reynolds, 2012, Bioorganic & medicinal chemistry letters.

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.

X. Tong, H. Huang, E. Xia, 2009, Antiviral research.

Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection

Tara L. Kieffer, A. Kwong, M. Tausek, 2008 .

Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor.

Rebecca T. Ruck, Yongxin Han, J. Howe, 2016, ACS medicinal chemistry letters.

Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2

E. Asante-Appiah, P. Qiu, F. Lahser, 2019, Antimicrobial Agents and Chemotherapy.

Characterization of resistance mutations against HCV ketoamide protease inhibitors.

X. Tong, R. Ralston, Zhuyan Guo, 2008, Antiviral research.

Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

R. Bowden, E. Barnes, D. Bonsall, 2018, Infection and drug resistance.

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

D. Graham, J. Howe, A. Howe, 2013, Journal of hepatology.

Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

X. Tong, R. Ralston, B. Feld, 2010, Antimicrobial Agents and Chemotherapy.

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin

J. Howe, A. Howe, J. Long, 2014, Open forum infectious diseases.

A sensitive enzyme-linked immunosorbent assay (ELISA) against the major EBV-associated antigens. I. Correlation between ELISA and immunofluorescence titers using purified antigens.

R. Chase, G. Pearson, J. Luka, 1984, Journal of immunological methods.

[432] FAVORABLE CROSS-RESISTANCE PROFILE OF TWO NOVEL HEPATITIS C VIRUS INHIBITORS, SCH-503034 AND HCV-796, AND ENHANCED ANTI-REPLICON ACTIVITY MEDIATED BY THE COMBINED USE OF BOTH COMPOUNDS

X. Tong, E. Emini, R. Ralston, 2007 .

Mutations Conferring Resistance to SCH6, a Novel Hepatitis C Virus NS3/4A Protease Inhibitor

S. Lemon, X. Tong, N. Bourne, 2006, Journal of Biological Chemistry.

Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.

R. Chase, B. Vroman, G. Pearson, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a

E. Asante-Appiah, Zhuyan Guo, Yuan Hu, 2017, The Journal of Biological Chemistry.

P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325

Qian Huang, Adam T. Gates, M. Rudd, 2015, ChemMedChem.

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

N. Butkiewicz, F. Gheyas, X. Tong, 2006, Antimicrobial Agents and Chemotherapy.

SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2.

A. Kwong, J. O'Connell, E. Rozhon, 1997, Antiviral Research.

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:

Weiying Yang, Zhuyan Guo, Andrea Hart, 2006, Journal of medicinal chemistry.

Nucleoside triphosphatase and RNA helicase activities associated with GB virus B nonstructural protein 3.

Z. Hong, W. Zhong, N. Yao, 1999, Virology.

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

X. Tong, B. Malcolm, A. Skelton, 2006, Antiviral research.

P0891 : Resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: The C-worthy study

P. Harrigan, A. Howe, C. Brumme, 2015 .

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study

William M. Lee, M. Colombo, R. Talwani, 2017, Hepatology.

Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system

G. Seelig, A. Kwong, Z. Hong, 1996, Journal of virology.

Generation of a Chimeric Hepatitis C Replicon Encoding a Genotype-6a NS3 Protease and Assessment of Boceprevir (SCH503034) Sensitivity and Drug-Associated Mutations

J. Howe, Zhuyan Guo, S. Locarnini, 2015, Antiviral therapy.

Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons

D. Nickle, E. Asante-Appiah, P. Qiu, 2017, Antimicrobial Agents and Chemotherapy.

A novel recombinant single‐chain hepatitis C virus ns3‐ns4a protein with improved helicase activity

A. Howe, B. Malcolm, J. Lau, 1999, Protein science : a publication of the Protein Society.

Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.

S. Tamura, S. Kemp, M. Lim-Wilby, 2006, Journal of medicinal chemistry.

Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors.

Robert Chase, Sony Agrawal, X. Tong, 2008, Biochemical pharmacology.

Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein.

R. Chase, G. Pearson, L. Qualtiere, 1982, Journal of immunology.

Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex.

A. Kwong, P. Weber, Z. Hong, 1998, Biochemistry.

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons

D. Hazuda, E. Asante-Appiah, A. Howe, 2016, Antimicrobial Agents and Chemotherapy.

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A

E. Asante-Appiah, F. Lahser, S. Agrawal, 2018, Antimicrobial Agents and Chemotherapy.

Synthesis and SAR of geminal substitutions at the C5' carbosugar position of pyrimidine-derived HCV inhibitors.

X. Tong, M. Maccoss, N. Bansal, 2012, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.

X. Tong, M. Maccoss, N. Bansal, 2012, Bioorganic & medicinal chemistry letters.

Interferon in Replicon Cells Enhances the Antiviral Activity of Alpha Suppresses Polyprotein Maturation and of Hepatitis C Virus NS 3 Protease , SCH 503034 , a Mechanism-Based Inhibitor

F. Gheyas, X. Tong, C. Jiang, 2005 .

Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.

Andrea Hart, Robert Chase, Sony Agrawal, 2009, Journal of medicinal chemistry.